ARK 每周股评 – 9/17/2022


We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Recursion Pharmaceuticals (RXRX)
-17%Shares of Recursion Pharmaceuticals traded down ~17% Friday, participating in a broad market slump catalyzed by macroeconomic uncertainty. On Tuesday, the company announced its launch of clinical trials for REC-4481 and REC-396, two drugs aiming to treat familial adenomatous polyposis and Clostridium difficile infection. Recursion is a young platform-based therapeutics company industrializing drug discovery. Its key differentiator, Recursion OS, integrates exponential growth technologies spanning wet and dry-lab biology with the goal of optimizing preclinical success.

注:周五,Recursion Pharmaceuticals的股票下跌了约17%,参与了由宏观经济不确定性催化的广泛的市场低迷。周二,该公司宣布启动REC-4481和REC-396的临床试验,这两种药物旨在治疗家族性腺瘤性息肉病和艰难梭菌感染。Recursion是一家年轻的基于平台的治疗公司,将药物发现产业化。其关键的差异化产品Recursion OS整合了跨越湿法和干法实验室生物学的指数增长技术,目的是优化临床前的成功。


上一篇 2022年9月18日 下午4:29
下一篇 2022年9月21日 下午2:07



您的电子邮箱地址不会被公开。 必填项已用*标注